Literature summary for 1.17.4.1 extracted from

Cappellacci, L.; Franchetti, P.; Vita, P.; Petrelli, R.; Lavecchia, A.; Jayaram, H.N.; Saiko, P.; Graser, G.; Szekeres, T.; Grifantini, M.
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3-C-methyladenosine derivatives (2008), J. Med. Chem., 51, 4260-4269.

Search for more literature for 1.17.4.1

Inhibitors

Inhibitors	Comment	Organism	Structure
6-chloro-9H-(3-C-methyl-2,3-di-O-acetyl-5-O-benzoyl-beta-D-ribofuranosyl)purine	-	Homo sapiens
additional information	construction and synthesis of ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3-C-methyladenosine derivatives, an unsubstituted N6-amino group is essential for optimal cytotoxicity of 3'-Me-Ado. The anticancer nucleosides act as antimetabolites after metabolic activation by phosphorylation to the corresponding 5'-di- or 5'-triphosphates, overview	Homo sapiens
N6-(2-furanylmethyl)-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-(2-thienylmethyl)-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-(3-pyrazolyl)-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-cyclobutyl-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-cycloheptyl-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-endo-norbonyl-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens
N6-phenyl-9H-(3-C-methyl-beta-D-ribofuranosyl)adenine	-	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
Caco-2 cell	a colon adenocarcinoma cell line	Homo sapiens	-
carcinoma cell	-	Homo sapiens	-
HL-60 cell	a promyelocytic leukemia cell line	Homo sapiens	-
HT-29 cell	a colon carcinoma cell line	Homo sapiens	-
K-562 cell	a myelogenous leukemia cell line	Homo sapiens	-
MCF-7 cell	a breast carcinoma cell line	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)